Immunotherapy plus chemo vs. standard chemo for esophageal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial compares two treatments given before surgery for esophageal cancer. One combines an immunotherapy drug (Toripalimab) with chemotherapy (nab-paclitaxel and platinum). The other uses a different standard chemotherapy regimen (DCF). The goal is to see which is better at shrinking tumors and improving outcomes for patients with resectable, locally advanced esophageal squamous cell carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that has not spread to other organs and can be surgically removed.
- You have not received any prior treatment for this cancer.
- Your overall health is good enough to undergo surgery and chemotherapy (ECOG score 0 or 1).
- Your heart, liver, kidney, and blood counts are within safe limits as tested by blood work.
- You agree to use effective birth control during and for 6 months after treatment if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial compares the current standard treatment (chemotherapy and radiation) with a newer approach that combines chemotherapy and immunotherapy before surgery for esophageal cancer. Participation may help determine if this new combination is more effective for you.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests adding an immunotherapy drug (toripalimab) to chemotherapy and low-dose radiation for people with esophageal cancer that did not shrink after initial treatment. The goal is to see if this combination can help when standard therapy stops working.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.